Literature DB >> 3108070

Major locus inheritance of apolipoprotein B in Utah pedigrees.

S J Hasstedt, L Wu, R R Williams.   

Abstract

A major locus that determines levels of apolipoprotein B (apoB) was revealed by likelihood analysis on 331 members of 36 pedigrees. The major locus explained 43.2% of the observed variance, with the remainder attributed to random environmental factors. Estimated mean apoB levels (mg/dl) were 110.5 +/- 2.5, 141.9 +/- 4.4, and 208.1 +/- 11.5 for low homozygotes, heterozygotes, and high homozygotes, respectively. The corresponding genotypic frequencies were 0.718, 0.259, and 0.023. The apoB locus explained 13% and 14% of the variance in total and low-density-lipoprotein cholesterol levels, respectively. Persons with elevated apoB had normal to high levels of total serum cholesterol and triglyceride and low to normal levels of high-density lipoprotein and apolipoprotein A-I. Sixteen members of three of the pedigrees were heterozygous for familial hypercholesterolemia (FH). Their apoB levels were estimated as 35.72 +/- 7.16 mg/dl above the apoB genotypic means, assuming that the two loci act independently. Therefore, two major loci, the FH locus and the apoB locus, affect two levels, apoB and LDL cholesterol.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3108070     DOI: 10.1002/gepi.1370040202

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  9 in total

Review 1.  Dissecting the genetic contribution to coronary heart disease.

Authors:  J W MacCluer; C M Kammerer
Journal:  Am J Hum Genet       Date:  1991-12       Impact factor: 11.025

2.  Pedigree and sib-pair linkage analysis suggest the apolipoprotein B gene is not the major gene influencing plasma apolipoprotein B levels.

Authors:  J Coresh; T H Beaty; P O Kwiterovich; S E Antonarakis
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

3.  Linkage and association analyses identify a candidate region for apoB level on chromosome 4q32.3 in FCHL families.

Authors:  Ellen M Wijsman; Joseph H Rothstein; Robert P Igo; John D Brunzell; Arno G Motulsky; Gail P Jarvik
Journal:  Hum Genet       Date:  2010-04-11       Impact factor: 4.132

4.  The polymorphism ApoB/4311 in patients with myocardial infarction and controls: the ECTIM Study.

Authors:  J F Moreel; G Roizes; A E Evans; D Arveiler; J P Cambou; C Souriau; H J Parra; E Desmarais; J C Fruchart; P Ducimetière
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

5.  Sources of interindividual variation in the quantitative levels of apolipoprotein B in pedigrees ascertained through a lipid clinic.

Authors:  G Pairitz; J Davignon; H Mailloux; C F Sing
Journal:  Am J Hum Genet       Date:  1988-09       Impact factor: 11.025

6.  Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis.

Authors:  M A Austin; M C King; K M Vranizan; B Newman; R M Krauss
Journal:  Am J Hum Genet       Date:  1988-12       Impact factor: 11.025

7.  Two amino acid substitutions in apolipoprotein B are in complete allelic association with the antigen group (x/y) polymorphism: evidence for little recombination in the 3' end of the human gene.

Authors:  A M Dunning; H H Renges; C F Xu; R Peacock; R Brasseur; G Laxer; M J Tikkanen; R Bütler; N Saha; A Hamsten
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

8.  Hypertension and sodium-lithium countertransport in Utah pedigrees: evidence for major-locus inheritance.

Authors:  S J Hasstedt; L L Wu; K O Ash; H Kuida; R R Williams
Journal:  Am J Hum Genet       Date:  1988-07       Impact factor: 11.025

9.  Variation at the apolipoprotein (apo) AI-CIII-AIV gene cluster and apo B gene loci is associated with lipoprotein and apolipoprotein levels in Italian children.

Authors:  C F Xu; M N Nanjee; J Savill; P J Talmud; F Angelico; M Del Ben; R Antonini; B Mazzarella; N Miller; S E Humphries
Journal:  Am J Hum Genet       Date:  1990-09       Impact factor: 11.025

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.